We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lecithin Found to Help Modulate Lipid Metabolism

By LabMedica International staff writers
Posted on 12 Aug 2009
An endogenous phospholipid and food additive from the lecithin family has been found to activate peroxisome proliferator-activated receptors (PPAR), a class of intracellular receptors that modulate carbohydrate and fat metabolism and adipose tissue differentiation. More...
Activating PPARs induces the transcription of a number of genes that facilitate lipid metabolism.

Investigators from Washington University School of Medicine (St. Louis, MO, USA) genetically engineered a line of mice to lack the gene for the enzyme fatty acid synthase (FAS). Results published in the July 30, 2009, online issue of the journal Cell revealed that these mice had lower fasting insulin levels than normal animals and were prone to develop fatty liver disease. These were the same indications that coincided with impaired PPAR-alpha expression.

While it was known that fibrate drugs could activate PPAR-alpha and restore normal lipid metabolism, the investigators sought an endogenous ligand that could perform the same function. To this end, they used mass spectroscopy and gene expression analysis to demonstrate that the lecithin component phosphatidylcholine (1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine) could bind to and activate PPAR-alpha. This finding was confirmed by showing that "knockdown” of the Cept1 gene, required for phosphatidylcholine synthesis, suppressed PPAR-alpha-dependent gene expression.

"To our surprise, animals missing fatty acid synthase in the liver were just like animals that could not make PPAR-alpha. They had lower fasting insulin levels, and they were prone to develop fatty liver disease,” explained senior author Dr. Clay F. Semenkovich, professor of endocrinology, metabolism, and lipid research at Washington University School of Medicine. "When we gave the animals fibrate drugs that activated PPAR-alpha, the mice returned to normal, leading us to suspect that fatty acid synthase also was involved in the activation of PPAR-alpha. Although we knew that fibrate drugs would regulate PPAR-alpha, we also knew that our ability to regulate the metabolism of fats and sugars was in place long before humans started making drugs. But until now, no one had identified how it worked.”

Related Links:
Washington University School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.